Back to Search
Start Over
Eco synthesized chitosan/zinc oxide nanocomposites as the next generation of nano-delivery for antibacterial, antioxidant, antidiabetic potential, and chronic wound repair.
- Source :
-
International journal of biological macromolecules [Int J Biol Macromol] 2023 Jul 01; Vol. 242 (Pt 1), pp. 124764. Date of Electronic Publication: 2023 May 05. - Publication Year :
- 2023
-
Abstract
- The present research work aimed at synthesizing chitosan-coated Zinc oxide nanocomposites (NS-CS/ZnONCs) by a bio-inspired method using an aqueous extract of Nigella sativa (NS) seeds and employing a quality-by-design approach (Box-Behnken design). The biosynthesized NS-CS/ZnONCs were physicochemically characterized and subjected to their in-vitro and in-vivo therapeutic potential. The zeta potential value of -11.2 mV and -12.6 mV indicated the stability of NS-mediated synthesized zinc oxide nanoparticles (NS-ZnONPs) and NS-CS/ZnONCs, respectively. The particle size of NS-ZnONPs and NS-CS/ZnONCs were 288.1 nm and 130.2 nm, respectively, with PDI of 0.198 and 0.158. NS-ZnONPs and NS-CS/ZnONCs showed superior radical scavenging abilities, excellent α-amylase, and α-glucosidase inhibitory activities. Also, NS-ZnONPs and NS-CS/ZnONCs demonstrated effective antibacterial activity against selected pathogens. Furthermore, NS-ZnONPs and NS-CS/ZnONCs demonstrated significant (p < 0.001) wound closure with 93.00 ± 0.43 % and 95.67 ± 0.43 % on the 15 <superscript>th</superscript> day of treatment at the dose of 14 mg/wound, compared to 93.42 ± 0.58 % of standard. Collagen turnover was represented by hydroxyproline, which was shown to be significantly (p < 0.001) higher in the NS-ZnONPs (60.70 ± 1.44 mg/g of tissue) and NS-CS/ZnONCs (66.10 ± 1.23 mg/g of tissue) treatment groups than in the control group (47.7 ± 0.81 mg/g of tissue). Thus the NS-ZnONPs and NS-CS/ZnONCs could effectively develop promising drugs to inhibit pathogens and chronic tissue repair.<br />Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Shailendra Shivaji Gurav has patent CHITOSAN AND ZINC OXIDE NANOCOMPOSITE pending to Licensee.<br /> (Copyright © 2023 Elsevier B.V. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 1879-0003
- Volume :
- 242
- Issue :
- Pt 1
- Database :
- MEDLINE
- Journal :
- International journal of biological macromolecules
- Publication Type :
- Academic Journal
- Accession number :
- 37148929
- Full Text :
- https://doi.org/10.1016/j.ijbiomac.2023.124764